Excerpts from RHB report

Analysts: Lee Cai Ling & Jarick Seet

Maintain BUY with unchanged DCF-derived TP of SGD0.48, 30% upside. 1H19 revenue of SGD44.6m (+9.4% YoY) was mainly contributed by the acquisition of Pheniks in Apr 2018.

S'pore Medical Group

Share price:
38 c

Target: 
48 c

2Q19 PATMI was at SGD3.5m (+3.5% YoY), bringing 1H19 PATMI to SGD6.8m (-1.1% YoY), accounting for 54% of our forecasts.

We believe the positive momentum will likely sustain. The stock is trading at 14x P/E vs peers’ 20x, offering an attractive upside potential.


Higher gross profit on steady gross margins. Gross profit increased by 10.4% and 11.3% in 2Q19 and 1H19 to SGD10.7m and SGD20.7m, due to stronger contributions from the higher-margin Diagnostic & Aesthetics segment.

bengteckliang5.18Dr Beng Teck Liang, CEO of Singapore Medical Group. NextInsight file photoGross margin remained unchanged YoY at 46% in 1H19. We expect gross margin to be slightly compressed in 2H19 with the addition of new headcount.

 Following through its expansion plan. The group will likely add a new gynaecologist, two new paediatricians, and a radiologist in 2H19. We understand that management intends to bring on board 10-12 specialists during the current financial year to grow its key specialist verticals (obstetrics, and gynaecology & paediatrics).

With an untapped cash position of SGD9.7m from the full drawdown of its convertible loan, we believe the group is well-positioned for overseas expansion into possible new markets such as Cambodia, Thailand and Malaysia, while further strengthening its footprint in Vietnam.

Conversion of convertible loan and proposed acquisition of additional shares in CityClinic Asia (CCAI) to capture opportunities in Vietnam. SMG has exercised its option to convert the convertible loan of USD0.69m to 177,670 ordinary shares, at the conversion price of USD3.88 apiece, and will acquire an additional 65,647 shares for USD0.26m from existing shareholders at the same price.

The group will hold an effective 24.4% in CCAI once the two transactions are completed. CCAI reported a net loss before tax of USD1.13m for FY18, and is likely to continue incurring losses in FY19F although we do not expect the losses to have a material impact on SMG. We believe it will take some time for the business to turn profitable.

 Reiterate BUY with unchanged DCF-based TP of SGD0.48. The stock is trading at 14x P/E vs peers’ 20x. We believe the steep discount compared to its peers offers a good opportunity to buy in.

On a fundamental perspective, we believe SMG still has the potential to grow through the addition of clinics/specialists and/or stepping up its partnership with its largest shareholder, CHA Healthcare, to explore projects in the region.


Full RHB report here.

UOBKH report is here


Share Prices

Counter NameLastChange
AEM Holdings1.920-0.010
AusGroup0.032-0.001
Avi-Tech Electronics0.415-0.005
Best World Int.1.360-
CEI0.955-
China Sunsine0.5250.015
CNMC GoldMine0.245-
CSE Global0.5450.010
Eagle HTrust USD0.5300.015
Food Empire0.6250.010
Golden Energy0.159-
GSS Energy0.0880.002
ISDN Holdings0.215-0.005
ISOTeam0.240-0.005
JB Foods0.650-0.005
KSH Holdings0.440-
Miyoshi0.030-
Moya Asia0.0670.002
Nordic Group0.280-
Oxley Holdings0.350-
Procurri0.475-
REX International0.1910.005
Riverstone0.950-
Roxy-Pacific0.400-
Sing Holdings0.390-
SingMedical0.3000.005
Straco Corp.0.6800.005
Sunningdale Tech1.310-0.020
Sunpower Group0.6150.025
The Trendlines0.087-
Tiong Seng0.2100.010
Uni-Asia Group0.7500.005
Yangzijiang Shipbldg1.100-0.030

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 1363 guests and no members online